Albers Jeffrey W. 4

What Happened Jeffrey W. Albers, a director of Kymera Therapeutics, was granted a derivative award on 2026-06-24 covering 6,068 shares. The Form 4 reports the acquisition as 6,068 shares at $0.00 (derivative instrument). A footnote clarifies this is a stock option that will vest in full upon the earlier of June 24, 2027 or the date of the company's next annual meeting. No shares were sold; this is a compensation grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-24; Form 4 filed: 2026-06-25 (appears timely).
• Instrument: Stock option (derivative) for 6,068 underlying shares; filing shows $0.00 cash paid at grant.
• Vesting: Vests in full upon earlier of June 24, 2027 or the next annual meeting (per footnote).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing timeliness: Not flagged as late in the provided data.

Context This was an equity compensation grant (stock option) to a director. Such awards are routine for executives and directors and do not by themselves indicate buying or selling sentiment. Because this is a derivative grant (an option that vests later), it does not represent immediate ownership of marketable shares unless and until exercised and any vesting conditions are met.